Table 4.

BMI and incidence of invasive breast cancer by treatment group

RaloxifeneTamoxifenPlacebo
BMINNo. of eventsHR (95% CI)NNo. of eventsHR (95% CI)NNo. of EventsHR (95% CI)
STAR/P-1 postmenopausala<25.02,808901.003,990811.001,085231.00
25.0–29.93,256950.92 (0.69–1.22)4,254951.07 (0.80–1.44)1,131381.77 (1.05–2.97)
≥30.03,3421081.07 (0.81–1.42)4,2981001.18 (0.88–1.58)993231.28 (0.72–2.28)
Ptrend0.610.260.36
P-1 premenopausalb<25.01,292131.001,304301.00
25.0–29.9891151.79 (0.85–3.76)894301.51 (0.91–2.50)
≥30.0736152.33 (1.10–4.90)747231.41 (0.82–2.43)
Ptrend0.020.17
  • aAdjusted for Gail score and age.

  • bAdjusted for Gail score.